<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01491022</url>
  </required_header>
  <id_info>
    <org_study_id>20110173</org_study_id>
    <nct_id>NCT01491022</nct_id>
  </id_info>
  <brief_title>A Randomized Trial to Evaluate Ampyra for Gait Impairment in Parkinson's Disease</brief_title>
  <official_title>A Randomized Trial to Evaluate Ampyra for Gait Impairment in Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Acorda Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of AMPYRA on a number of symptoms in
      Parkinson's disease. AMPYRA is a medication approved by FDA for gait dysfunction in multiple
      sclerosis. There are multiple studies to suggest that persons with multiple sclerosis benefit
      from this medication and have major improvements in gait after taking this medication.
      However, this medication was never studied in Parkinson's disease. This study aims to learn
      about possible benefits of AMPYRA in Parkinson's disease (PD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects with Parkinson's disease will be randomly assigned to two groups. One group will
      receive Ampyra first for 4 weeks, followed by 2 weeks break and than 4 weeks placebo while
      the second group will first receive placebo and then Ampyra.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Velocity</measure>
    <time_frame>baseline and 4 weeks</time_frame>
    <description>The primary outcome measure will be the change in gait velocity as measured with by 3-dimensional gait analysis system.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>United Parkinson's Disease Rating Scale Score(UPDRS) ,</measure>
    <time_frame>4 weeks</time_frame>
    <description>change in UPDRS score (motor) range 0-104, where 0 is good and 104 is worse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freezing of Gait Questionnaire (FOGQ)</measure>
    <time_frame>4 weeks</time_frame>
    <description>change in FOGQ score 0- 16, where 0 is normal, 16 is severely impaired</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Timed Up and Go (TUG) Score</measure>
    <time_frame>4 weeks</time_frame>
    <description>time required to perform TUG.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Timed 25-foot Walk Test (T25FW)</measure>
    <time_frame>4 weeks</time_frame>
    <description>time required to perform T25FW.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Stride Legth</measure>
    <time_frame>4 weeks</time_frame>
    <description>change in stride length as measured by 3 D capture analysis</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>Ampyra</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ampyra 10 mg po BID for 4 weeks followed by placebo 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>placebo 4 weeks followed by Ampyra 10 mg po BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ampyra first, then Placebo</intervention_name>
    <description>10 mg po bid for 4 weeks followed by placebo 4 weeks.</description>
    <arm_group_label>Ampyra</arm_group_label>
    <other_name>first intervention</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo first, then Ampyra</intervention_name>
    <description>placebo</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>second intervention</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Idiopathic PD with stage Hoehn and Yahr Stage&gt;2-3 and with gait freezing or postural
             instability.

          -  On stable dosage dopamine agonist/levodopa, and expected to remain on the same dosage
             of treatment for the duration of study

          -  Age less than 80, onset of disease at age more than 45.

          -  Able to give consent

        Exclusion Criteria:

          -  Past medical history of seizures,

          -  History of renal insufficiency,

          -  History of cardiac arrhythmia,

          -  Severe arthritis,

          -  Women of childbearing potential,

          -  Cognitive impairment

          -  Age more than 80.

          -  PD patients stage 4 H&amp;Y

          -  PD patient with recent introduction of dopamine agonist or IMAO B

          -  PD patients participating in other studies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Corneliu Luca</last_name>
    <role>Study Chair</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 8, 2011</study_first_submitted>
  <study_first_submitted_qc>December 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2011</study_first_posted>
  <results_first_submitted>March 2, 2016</results_first_submitted>
  <results_first_submitted_qc>March 1, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 13, 2017</results_first_posted>
  <last_update_submitted>December 5, 2017</last_update_submitted>
  <last_update_submitted_qc>December 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Corneliu C Luca</investigator_full_name>
    <investigator_title>Neurology Instructor</investigator_title>
  </responsible_party>
  <keyword>parkinson's</keyword>
  <keyword>gait dysfunction</keyword>
  <keyword>ampyra</keyword>
  <keyword>4-aminopyridine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>4-Aminopyridine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ampyra Then Placebo</title>
          <description>Ampyra 10 mg po BID for 4 weeks followed by 2 weeks washout followed by 4 weeks placebo</description>
        </group>
        <group group_id="P2">
          <title>Placebo Then Ampyra</title>
          <description>placebo for 4 weeks followed by 2 weeks washout followed by 4 weeks Ampyra 10 mg po BID</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Intervention 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>2 Week Washout</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Intervention 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ampyra Then Placebo</title>
          <description>Ampyra 10 mg po BID for 4 weeks followed by 2 weeks washout followed by 4 weeks placebo</description>
        </group>
        <group group_id="B2">
          <title>Placebo Then Ampyra</title>
          <description>Placebo for 4 weeks followed by 2 weeks washout followed by Ampyra 10 mg po bid for 4 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="22"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.6" spread="10.8"/>
                    <measurement group_id="B2" value="67.4" spread="5.9"/>
                    <measurement group_id="B3" value="67.5" spread="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Velocity</title>
        <description>The primary outcome measure will be the change in gait velocity as measured with by 3-dimensional gait analysis system.</description>
        <time_frame>baseline and 4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ampyra</title>
            <description>Ampyra 10 mg po BID
Dalfampridine: 10 mg po bid for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo: placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Velocity</title>
          <description>The primary outcome measure will be the change in gait velocity as measured with by 3-dimensional gait analysis system.</description>
          <units>m/s</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.03"/>
                    <measurement group_id="O2" value="0.05" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>United Parkinson's Disease Rating Scale Score(UPDRS) ,</title>
        <description>change in UPDRS score (motor) range 0-104, where 0 is good and 104 is worse.</description>
        <time_frame>4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ampyra</title>
            <description>Ampyra 10 mg po BID for 4 weeks followed by placebo 4 weeks
Ampyra first, then Placebo: 10 mg po bid for 4 weeks followed by placebo 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo 4 weeks followed by Ampyra 10 mg po BID
placebo first, then Ampyra: placebo</description>
          </group>
        </group_list>
        <measure>
          <title>United Parkinson's Disease Rating Scale Score(UPDRS) ,</title>
          <description>change in UPDRS score (motor) range 0-104, where 0 is good and 104 is worse.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.22" spread="14.4"/>
                    <measurement group_id="O2" value="35.55" spread="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Freezing of Gait Questionnaire (FOGQ)</title>
        <description>change in FOGQ score 0- 16, where 0 is normal, 16 is severely impaired</description>
        <time_frame>4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ampyra Then Placebo</title>
            <description>Ampyra 10 mg po BID for 4 weeks followed by 2 weeks washout followed by 4 weeks placebo</description>
          </group>
          <group group_id="O2">
            <title>Placebo Then Ampyra</title>
            <description>placebo for 4 weeks followed by 2 weeks washout followed by 4 weeks Ampyra 10 mg po BID</description>
          </group>
        </group_list>
        <measure>
          <title>Freezing of Gait Questionnaire (FOGQ)</title>
          <description>change in FOGQ score 0- 16, where 0 is normal, 16 is severely impaired</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.16" spread="4.9"/>
                    <measurement group_id="O2" value="13.4" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Timed Up and Go (TUG) Score</title>
        <description>time required to perform TUG.</description>
        <time_frame>4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ampyra Then Placebo</title>
            <description>Ampyra 10 mg po BID for 4 weeks followed by 2 weeks washout followed by 4 weeks placebo</description>
          </group>
          <group group_id="O2">
            <title>Placebo Then Ampyra</title>
            <description>placebo for 4 weeks followed by 2 weeks washout followed by 4 weeks Ampyra 10 mg po BID</description>
          </group>
        </group_list>
        <measure>
          <title>Timed Up and Go (TUG) Score</title>
          <description>time required to perform TUG.</description>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.25" spread="15.4"/>
                    <measurement group_id="O2" value="20.6" spread="15.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Timed 25-foot Walk Test (T25FW)</title>
        <description>time required to perform T25FW.</description>
        <time_frame>4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ampyra Then Placebo</title>
            <description>Ampyra 10 mg po BID for 4 weeks followed by 2 weeks washout followed by 4 weeks placebo</description>
          </group>
          <group group_id="O2">
            <title>Placebo Then Ampyra</title>
            <description>placebo for 4 weeks followed by 2 weeks washout followed by 4 weeks Ampyra 10 mg po BID</description>
          </group>
        </group_list>
        <measure>
          <title>Timed 25-foot Walk Test (T25FW)</title>
          <description>time required to perform T25FW.</description>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.6" spread="5.0"/>
                    <measurement group_id="O2" value="11.8" spread="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Stride Legth</title>
        <description>change in stride length as measured by 3 D capture analysis</description>
        <time_frame>4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ampyra</title>
            <description>Ampyra 10 mg po BID for 4 weeks followed by placebo 4 weeks
Ampyra first, then Placebo: 10 mg po bid for 4 weeks followed by placebo 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo 4 weeks followed by Ampyra 10 mg po BID
placebo first, then Ampyra: placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Stride Legth</title>
          <description>change in stride length as measured by 3 D capture analysis</description>
          <units>meters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.04"/>
                    <measurement group_id="O2" value="0.05" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>at 10 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ampyra</title>
          <description>Ampyra 10 mg po BID
Dalfampridine: 10 mg po bid for 4 weeks</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>placebo: placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>urinary tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>dizzines</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>balance worsening</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Corneliu Luca</name_or_title>
      <organization>University of Miami</organization>
      <phone>3052432235</phone>
      <email>cluca@med.miami.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

